Pancreatic cancer initiates an immune system response
Studying pancreatic ductal adenocarcinoma tumours, researchers discovered 25 antibodies that responded to antigens.
List view / Grid view
Studying pancreatic ductal adenocarcinoma tumours, researchers discovered 25 antibodies that responded to antigens.
Tracy Saveria, James Roberts and Brian Finrow from Lumen Bioscience discuss progress in the aspiration for global vaccine access and how Lumen Bioscience’s inhalation malaria vaccine represents a major step towards it.
Dr Katie Abouzahr outlines how precision targeting utilising the neonatal fragment crystallisable receptor pathway may provide accessible new treatments for autoantibody diseases.
This articles aims to drive understanding in Antibody Drug Conjugate (ADC) drug development to improve patient outcomes. Petra Dieterich, Ian Glassford, and Jeff Mocny, Scientific Leaders at Abzena discuss real-world data that is challenging traditional scientific thinking on the ADC therapeutic window. The authors also explore the need for further…
Swiss researchers have found a new class of 'good autoantibodies', which are associated with a favourable course and lower risk of long-Covid.
US scientists have outlined the structure and function of the first FDA approved drug for the Ebola virus.
An AI strategy developed by US scientists could accelerate the development of new antibody drugs.
US researchers find that SARS-CoV-2 bivalent antibodies can continue to neutralise Omicron and Omicron lineages.
As COVID-19 continues to evolve, researchers are still on the lookout for new ways to protect against the virus. Drug Target Review brings you some of the most recent pre-clinical developments.
Drug Target Review’s Ria Kakkad recently spoke with Dr Jane Osbourn about her experience as a woman in STEM.
Drug Target Review’s Ria Kakkad recently travelled to Barcelona to attend PEGS Europe’s Protein and Antibody Engineering Summit. In this article, she shares her highlights from the event.
Researchers find monoclonal antibodies provided nearly complete protection against EBV infection and lymphoma when tested in mice.
Antibody therapy has been a critical part of the COVID-19 research campaign to treat severe cases. Unfortunately, despite many promising candidates, scientists have yet to find one that passes clinical trials. This article by Drug Target Review’s Ria Kakkad highlights some of the most recent developments in the search for COVID-19…
Scientists have discovered antibodies that are effective against many different COVID-19 variants.
The monoclonal antibody 19A11 binds E-cadherin, a protein that helps cells stick together, especially in epithelial layers that line the skin, the gut and other organs.